Zufar Gabbasov1, Sergey Kozlov2, Svetlana Byazrova2, Olga Saburova2, Ivan Melnikov2, Martin Caprnda3, Eduard Curilla4, Ludovit Gaspar5, Peter Kruzliak6,7, Vladimir Smirnov2. 1. Laboratory of Stem Cells, Institute of Experimental Cardiology, Cardiology Research Center, 3rd Cherepkovskaya Street 15A, 121552, Moscow, Russia. zufargabbasov@yandex.ru. 2. Laboratory of Stem Cells, Institute of Experimental Cardiology, Cardiology Research Center, 3rd Cherepkovskaya Street 15A, 121552, Moscow, Russia. 3. Comenius University and University Hospital, Mickiewiczova 13, 81369, Bratislava, Slovakia. 4. Department of Cardiology, East Slovak Institute of Cardiovascular Diseases, Kosice, Slovakia. 5. Comenius University and University Hospital, Mickiewiczova 13, 81369, Bratislava, Slovakia. ludovitgaspar@gmail.com. 6. Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackeho 1946/1, 61242, Brno, Czech Republic. kruzliakpeter@gmail.com. 7. Masaryk University, Brno, Czech Republic. kruzliakpeter@gmail.com.
Abstract
OBJECTIVE: The aim of this study was to assess CD45-positive platelets (CD45+ platelets) involvement in restenosis development after drug-eluting stent (DES) implantation in patients with stable coronary artery disease (CAD). METHODS: The study comprised 126 male and female patients with stable angina pectoris, who underwent elective coronary stenting with DES and follow-up angiography within 6-12 months. The patients were assigned to the group with restenosis (n = 53) or group without restenosis (n = 73) according to the follow-up angiograms. In both groups we compared the level in blood of CD45+ platelets, the clinical, laboratory and angiographic variables, which may affect the development of restenosis. We have also constructed a logit regression model for prognosis of restenosis occurrence after DES implantation. RESULTS: The blood count of CD45+ platelets was higher in patients with restenosis than in patients without: 0.82 % (0.58; 1.12) vs. 0.34 % (0.20; 0.68), p < 0.001, data are expressed as median (lower quartile; upper quartile). By binary comparisons of more than 35 different clinical, laboratory and angiographic variables we identified 8 significant risk factors for the development of stent restenosis after DES. In order to define the risk of the development of restenosis, we have built a logit regression model. The resulting logit regression equation included the level of CD45+ platelets, the neutrophil to lymphocyte ratio (NLR), small diameter arteries stenting and the number of simultaneously implanted stents in one patient. Receiver operating characteristic (ROC) curve analysis has demonstrated the high prognostic value of the resulting logit regression equation with an area under the curve (AUC) of 0.91 % (p < 0.001). CONCLUSIONS: The acquired data indicate the presence of a close relationship between circulating CD45+ platelets and restenosis development after DES implantation in patients with stable CAD.
OBJECTIVE: The aim of this study was to assess CD45-positive platelets (CD45+ platelets) involvement in restenosis development after drug-eluting stent (DES) implantation in patients with stable coronary artery disease (CAD). METHODS: The study comprised 126 male and female patients with stable angina pectoris, who underwent elective coronary stenting with DES and follow-up angiography within 6-12 months. The patients were assigned to the group with restenosis (n = 53) or group without restenosis (n = 73) according to the follow-up angiograms. In both groups we compared the level in blood of CD45+ platelets, the clinical, laboratory and angiographic variables, which may affect the development of restenosis. We have also constructed a logit regression model for prognosis of restenosis occurrence after DES implantation. RESULTS: The blood count of CD45+ platelets was higher in patients with restenosis than in patients without: 0.82 % (0.58; 1.12) vs. 0.34 % (0.20; 0.68), p < 0.001, data are expressed as median (lower quartile; upper quartile). By binary comparisons of more than 35 different clinical, laboratory and angiographic variables we identified 8 significant risk factors for the development of stent restenosis after DES. In order to define the risk of the development of restenosis, we have built a logit regression model. The resulting logit regression equation included the level of CD45+ platelets, the neutrophil to lymphocyte ratio (NLR), small diameter arteries stenting and the number of simultaneously implanted stents in one patient. Receiver operating characteristic (ROC) curve analysis has demonstrated the high prognostic value of the resulting logit regression equation with an area under the curve (AUC) of 0.91 % (p < 0.001). CONCLUSIONS: The acquired data indicate the presence of a close relationship between circulating CD45+ platelets and restenosis development after DES implantation in patients with stable CAD.
Authors: M Balli; H Taşolar; M Çetin; K Tekin; Ç E Çağliyan; S Türkmen; M Yilmaz; Z Elbasan; D Y Şahin; M Çayli Journal: Eur Rev Med Pharmacol Sci Date: 2015-05 Impact factor: 3.507
Authors: Jonathan R Nebeker; Renu Virmani; Charles L Bennett; Jennifer M Hoffman; Matthew H Samore; Jorge Alvarez; Charles J Davidson; June M McKoy; Dennis W Raisch; Brian K Whisenant; Paul R Yarnold; Steven M Belknap; Dennis P West; Jonathan E Gage; Richard E Morse; Gordana Gligoric; Laura Davidson; Marc D Feldman Journal: J Am Coll Cardiol Date: 2005-12-01 Impact factor: 24.094
Authors: Aloke V Finn; Gaku Nakazawa; Michael Joner; Frank D Kolodgie; Erik K Mont; Herman K Gold; Renu Virmani Journal: Arterioscler Thromb Vasc Biol Date: 2007-05-17 Impact factor: 8.311